# Lactobacillus paracasei ATCC 25302

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/lactobacillus-paracasei-atcc-25302
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-04-02
**Evidence Score:** 2 / 10
**Category:** Fermented/Probiotic
**Also Known As:** L. paracasei ATCC 25302, ATCC 25302, Lactobacillus paracasei strain ATCC 25302, LPC-ATCC25302, L. paracasei type strain 25302

## Overview

Lactobacillus paracasei ATCC 25302 is a [probiotic](/ingredients/condition/gut-health) strain characterized by exceptionally high adhesion to intestinal epithelial cells (87.15% adhesion rate to Caco-2 cells), enabling colonization and competitive exclusion of pathogens. Its primary mechanisms include secretion of bacteriocins and organic acids that inhibit pathogenic bacteria such as S. aureus, E. coli, and H. pylori, alongside modulation of adipogenic signaling pathways.

## Health Benefits

• May support intestinal health through strong adhesion to intestinal cells (87.15% adhesion rate to Caco-2 cells) - preliminary evidence
• Demonstrates [antimicrobial](/ingredients/condition/immune-support) activity against pathogens including S. aureus, E. coli, and H. pylori - in vitro studies only
• Shows potential antiadipogenic effects with ~50% reduction in lipid accumulation in cell studies - preliminary evidence
• Exhibits cholesterol-reducing properties in laboratory settings - no human trial data
• Demonstrates tolerance to gastric juice and bile salts suggesting [probiotic](/ingredients/condition/gut-health) viability - in vitro evidence only

## Mechanism of Action

L. paracasei ATCC 25302 adheres to intestinal epithelial cells via surface-layer proteins and mucus-binding proteins, competitively excluding pathogens from colonization sites. It produces lactic acid, acetic acid, and bacteriocin-like inhibitory substances (BLIS) that disrupt pathogen cell membranes and lower luminal pH, inhibiting growth of S. aureus, E. coli, and H. pylori. Its antiadipogenic effects are proposed to occur through downregulation of key adipogenic transcription factors including PPAR-γ and C/EBPα, reducing lipid accumulation in adipocytes.

## Clinical Summary

Current evidence for L. paracasei ATCC 25302 derives predominantly from in vitro studies, including Caco-2 cell adhesion assays and agar diffusion [antimicrobial](/ingredients/condition/immune-support) assays, with limited human clinical trial data specific to this strain. The 87.15% adhesion rate to Caco-2 cells is among the higher rates reported for Lactobacillus strains and suggests strong colonization potential, though in vitro adhesion does not always predict in vivo efficacy. Antiadipogenic activity has been observed in cell-based models, but human studies confirming weight or fat mass outcomes have not been published for this specific strain. Overall, the evidence base is preliminary and requires well-designed randomized controlled trials before definitive health claims can be substantiated.

## Nutritional Profile

As a [probiotic](/ingredients/condition/gut-health) strain, Lactobacillus paracasei ATCC 25302 does not contribute meaningful macronutrients or micronutrients in typical supplemental doses (10^8–10^10 CFU per serving). Its primary bioactive contributions are metabolic byproducts produced during fermentation and colonization: short-chain fatty acids (SCFAs) including acetate and lactate (primary end-products of homofermentative [metabolism](/ingredients/condition/weight-management)), bacteriocin-like inhibitory substances (BLIS) responsible for documented [antimicrobial](/ingredients/condition/immune-support) activity against S. aureus, E. coli, and H. pylori, and exopolysaccharides (EPS) that mediate the high adhesion rate (87.15%) to Caco-2 intestinal epithelial cells. The strain produces conjugated linoleic acid (CLA) precursors in small amounts during fermentation. It may generate B-vitamins (particularly B12 and folate) as metabolic byproducts, though quantities are strain- and substrate-dependent and not well-quantified for ATCC 25302 specifically. Bile salt hydrolase (BSH) activity is documented for this strain, enabling cholesterol co-precipitation — the mechanism behind its cholesterol-lowering potential. Bioavailability is contingent on gastric acid survival; encapsulation or co-administration with food significantly improves viable cell delivery to the colon.

## Dosage & Preparation

No clinically studied dosage ranges are available for ATCC 25302 as it lacks specific human trial data. Related L. paracasei strains have been tested in clinical settings but without specified CFU counts or standardized dosing protocols in available abstracts. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

L. paracasei strains are generally recognized as safe (GRAS) and have a long history of use in fermented foods, with most adverse effects limited to mild, transient gastrointestinal symptoms such as bloating or gas during initial use. Individuals who are immunocompromised, critically ill, or have central venous catheters should exercise caution with any [probiotic](/ingredients/condition/gut-health) supplementation due to rare but documented risks of bacteremia and sepsis in vulnerable populations. No specific drug interactions have been formally established for ATCC 25302, though concurrent use with systemic antibiotics may reduce probiotic viability; spacing doses by at least two hours is a common precautionary recommendation. Pregnancy and breastfeeding safety data specific to this strain are insufficient, and consultation with a healthcare provider is advised before use in these populations.

## Scientific Research

No human clinical trials have been conducted specifically on ATCC 25302. Related L. paracasei strains have shown mixed results in RCTs: Lpc-37 was found safe but ineffective for stress reduction in university students (PMID: 37662485), while another Lpc-37 trial reported improvements in psychological quality of life (PMID: 33385020), and strain N1115 was tested for gut development in children with confirmed safety (PMID: 34760234).

## Historical & Cultural Context

No historical or traditional medicine use is documented for ATCC 25302 or specific L. paracasei strains. This is a modern type strain isolated specifically for research purposes rather than derived from traditional fermentation or medicinal systems.

## Synergistic Combinations

Lactobacillus paracasei ATCC 25302 pairs strongly with [prebiotic](/ingredients/condition/gut-health) fibers such as inulin (5–10g/day) and fructooligosaccharides (FOS), which selectively ferment in the colon to provide substrate for SCFA production, amplifying the strain's colonization capacity and extending its residence time — this prebiotic-probiotic synbiotic effect has been shown to increase viable probiotic counts by 1–2 log CFU in the gut. Co-administration with Lactobacillus rhamnosus GG or Bifidobacterium longum creates complementary [antimicrobial](/ingredients/condition/immune-support) and epithelial barrier coverage, as these strains occupy distinct adhesion sites on intestinal mucosa and produce overlapping yet non-redundant bacteriocins, collectively broadening pathogen inhibition spectra beyond what ATCC 25302 achieves alone against S. aureus and E. coli. Pairing with phytosterols (plant sterols, 1.5–3g/day) creates an additive cholesterol-lowering mechanism — phytosterols competitively inhibit cholesterol absorption in the small intestine while L. paracasei ATCC 25302's bile salt hydrolase activity deconjugates bile acids in the colon, reducing cholesterol reabsorption through an independent pathway, making this combination particularly relevant given the strain's documented antiadipogenic effects.

## Frequently Asked Questions

### What makes Lactobacillus paracasei ATCC 25302 different from other probiotic strains?

L. paracasei ATCC 25302 is distinguished by its exceptionally high intestinal adhesion rate of 87.15% to Caco-2 epithelial cells, which is notably higher than many commercially used probiotic strains. This strong adhesion is attributed to specific surface-layer proteins that facilitate attachment to intestinal mucosa, potentially enhancing its ability to colonize the gut and exert sustained probiotic effects compared to strains with lower adhesion capacity.

### Can Lactobacillus paracasei ATCC 25302 help with H. pylori infection?

In vitro studies demonstrate that L. paracasei ATCC 25302 produces inhibitory substances, including bacteriocins and organic acids, that exhibit antimicrobial activity against H. pylori in laboratory settings. However, these findings are based solely on cell and agar diffusion models, and no human clinical trials have evaluated this strain specifically for H. pylori eradication or adjunctive therapy, so it cannot currently be recommended as a treatment for H. pylori infection.

### Does Lactobacillus paracasei ATCC 25302 help with weight loss or fat reduction?

Preliminary in vitro research suggests L. paracasei ATCC 25302 may possess antiadipogenic properties by downregulating transcription factors PPAR-γ and C/EBPα, which are central regulators of fat cell differentiation and lipid storage. These findings are derived from cell-based models only, and no human clinical trials have confirmed that supplementation with this strain leads to measurable reductions in body fat or weight, so claims of weight loss benefits remain speculative at this stage.

### What is the recommended dosage for Lactobacillus paracasei ATCC 25302 supplements?

No evidence-based dosage has been established specifically for L. paracasei ATCC 25302, as human clinical trials for this strain are lacking. General probiotic dosing conventions typically range from 1 billion to 10 billion CFU (colony-forming units) per day for gut health applications, but optimal dosing for this specific strain's antimicrobial or antiadipogenic effects remains unknown and should be determined in consultation with a healthcare provider.

### Is Lactobacillus paracasei ATCC 25302 safe to take with antibiotics?

Like most probiotic strains, L. paracasei ATCC 25302 is susceptible to being killed by systemic antibiotics when taken simultaneously, which reduces its viability and potential benefits. To minimize this interaction, it is commonly recommended to space probiotic doses at least two hours apart from antibiotic doses; however, no strain-specific pharmacokinetic studies have been conducted for ATCC 25302 to confirm the optimal timing or whether this strategy preserves sufficient viable cells.

### Does Lactobacillus paracasei ATCC 25302 survive stomach acid to reach the intestines?

Lactobacillus paracasei ATCC 25302 demonstrates acid tolerance that allows it to survive gastric conditions and reach the small intestine where it exerts its benefits. Its strong adhesion capability (87.15% to intestinal epithelial cells) suggests effective colonization after surviving the acidic environment. However, survival rates can vary based on formulation type, enteric coating, and individual stomach pH levels.

### Can Lactobacillus paracasei ATCC 25302 be taken alongside other probiotic strains?

Yes, Lactobacillus paracasei ATCC 25302 can generally be combined with other probiotic strains, as multi-strain formulas are commonly used to promote diverse microbial communities in the gut. Its specific mechanisms (antimicrobial activity and intestinal adhesion) may complement strains with different functions. However, it is advisable to follow product instructions or consult a healthcare provider to ensure compatibility and appropriate dosing of combined strains.

### What is the shelf stability of Lactobacillus paracasei ATCC 25302 supplements?

Lactobacillus paracasei ATCC 25302 is sensitive to heat, moisture, and light exposure, which can reduce viability during storage. Most quality supplements containing this strain are stored in refrigerated conditions or packaged with desiccants and protective coatings to maintain potency. Check product labels for specific storage instructions and expiration dates, as viability at the time of consumption is critical for effectiveness.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*